Ahsan S Farooqi1, Emma B Holliday1, Pamela K Allen1, Xiong Wei1, James D Cox1, Ritsuko Komaki2. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States. 2. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States. Electronic address: rkomaki@mdanderson.org.
Abstract
PURPOSE: Prophylactic cranial irradiation (PCI) can improve overall survival (OS) and suppress brain metastases (BM) in patients with limited-stage small cell lung cancer (LS-SCLC) after complete response to primary therapy. However, PCI can be toxic. We sought to identify characteristics of patients who may not benefit from PCI. METHODS: We identified 658 patients who received chemoradiotherapy at MD Anderson in 1986-2012; 364 received PCI and 294 did not. Median follow-up time was 21.2months (range 1.2-240.8months). Cox proportional hazards regression, competing-risk regression, and Kaplan-Meier analyses were used to identify factors influencing OS and BM. RESULTS: PCI reduced risks of death [HR 0.73, 95% CI 0.61-0.88, P=0.001] and BM [HR 0.54, 95% CI 0.39-0.76, P<0.001]. Having tumors ⩾5cm increased the risk of BM [HR 1.77, 95% CI 1.22-2.55, P=0.002] but not death [HR 1.16, 95% CI 0.96-1.40, P=0.114]. Among patients ⩾70years with ⩾5-cm tumors, PCI did not improve OS [2-year rates 39.4% vs 40.9%, P=0.739]. CONCLUSIONS: PCI remains standard therapy after complete response to chemoradiotherapy for LS-SCLC. However, older patients may be at risk from comorbidity or extracranial disease. Further work is warranted to identify patients who may not benefit from PCI.
PURPOSE: Prophylactic cranial irradiation (PCI) can improve overall survival (OS) and suppress brain metastases (BM) in patients with limited-stage small cell lung cancer (LS-SCLC) after complete response to primary therapy. However, PCI can be toxic. We sought to identify characteristics of patients who may not benefit from PCI. METHODS: We identified 658 patients who received chemoradiotherapy at MD Anderson in 1986-2012; 364 received PCI and 294 did not. Median follow-up time was 21.2months (range 1.2-240.8months). Cox proportional hazards regression, competing-risk regression, and Kaplan-Meier analyses were used to identify factors influencing OS and BM. RESULTS:PCI reduced risks of death [HR 0.73, 95% CI 0.61-0.88, P=0.001] and BM [HR 0.54, 95% CI 0.39-0.76, P<0.001]. Having tumors ⩾5cm increased the risk of BM [HR 1.77, 95% CI 1.22-2.55, P=0.002] but not death [HR 1.16, 95% CI 0.96-1.40, P=0.114]. Among patients ⩾70years with ⩾5-cm tumors, PCI did not improve OS [2-year rates 39.4% vs 40.9%, P=0.739]. CONCLUSIONS:PCI remains standard therapy after complete response to chemoradiotherapy for LS-SCLC. However, older patients may be at risk from comorbidity or extracranial disease. Further work is warranted to identify patients who may not benefit from PCI.
Authors: Vinai Gondi; Wolfgang A Tome; James Marsh; Aaron Struck; Amol Ghia; Julius V Turian; Søren M Bentzen; John S Kuo; Deepak Khuntia; Minesh P Mehta Journal: Radiother Oncol Date: 2010-04-12 Impact factor: 6.280
Authors: Paul D Brown; Stephanie Pugh; Nadia N Laack; Jeffrey S Wefel; Deepak Khuntia; Christina Meyers; Ali Choucair; Sherry Fox; John H Suh; David Roberge; Vivek Kavadi; Soren M Bentzen; Minesh P Mehta; Deborah Watkins-Bruner Journal: Neuro Oncol Date: 2013-08-16 Impact factor: 12.300
Authors: Brian E Lally; Ann M Geiger; James J Urbanic; Jerome M Butler; Stacy Wentworth; Michael C Perry; Lynn D Wilson; Janet K Horton; Frank C Detterbeck; Antonius A Miller; Charles R Thomas; A William Blackstock Journal: Lung Cancer Date: 2008-10-02 Impact factor: 5.705
Authors: Abraham J Wu; Andrea Gillis; Amanda Foster; Kaitlin Woo; Zhigang Zhang; Daphna Y Gelblum; Robert J Downey; Kenneth E Rosenzweig; Leonard Ong; Carmen A Perez; M Catherine Pietanza; Lee Krug; Charles M Rudin; Andreas Rimner Journal: Radiother Oncol Date: 2017-08-01 Impact factor: 6.280
Authors: Daniel E Oliver; Olivia G Donnelly; G Daniel Grass; Arash O Naghavi; George Q Yang; Thomas J Dilling; Bradford A Perez Journal: J Thorac Dis Date: 2018-07 Impact factor: 2.895
Authors: Benjamin H Lok; Jennifer Ma; Amanda Foster; Carmen A Perez; Weiji Shi; Zhigang Zhang; Bob T Li; Charles M Rudin; Andreas Rimner; Abraham J Wu Journal: Adv Radiat Oncol Date: 2017-08-08
Authors: Michael Yan; Tzen S Toh; Patricia E Lindsay; Jessica Weiss; Katrina Hueniken; Christy Yeung; Vijithan Sugumar; Dixon Pinto; Tony Tadic; Alexander Sun; Andrea Bezjak; John Cho; Srinivas Raman; Meredith Giuliani; Fabio Ynoe Moraes; Geoffrey Liu; Andrew J Hope; Benjamin H Lok Journal: Clin Transl Radiat Oncol Date: 2021-07-08